278 related articles for article (PubMed ID: 35533701)
1. Mass drug administration of ivermectin, diethylcarbamazine, plus albendazole compared with diethylcarbamazine plus albendazole for reduction of lymphatic filariasis endemicity in Papua New Guinea: a cluster-randomised trial.
Laman M; Tavul L; Karl S; Kotty B; Kerry Z; Kumai S; Samuel A; Lorry L; Timinao L; Howard SC; Makita L; John L; Bieb S; Wangi J; Albert JM; Payne M; Weil GJ; Tisch DJ; Bjerum CM; Robinson LJ; King CL
Lancet Infect Dis; 2022 Aug; 22(8):1200-1209. PubMed ID: 35533701
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial.
Tavul L; Laman M; Howard C; Kotty B; Samuel A; Bjerum C; O'Brian K; Kumai S; Amuga M; Lorry L; Kerry Z; Kualawi M; Karl S; Makita L; John LN; Bieb S; Wangi J; Weil GJ; Goss CW; Tisch DJ; Pomat W; King CL; Robinson LJ
PLoS Negl Trop Dis; 2022 Feb; 16(2):e0010096. PubMed ID: 35139070
[TBL] [Abstract][Full Text] [Related]
3. An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia.
Supali T; Djuardi Y; Christian M; Iskandar E; Alfian R; Maylasari R; Destani Y; Lomiga A; Minggu D; Lew D; Bogus J; Weil GJ; Fischer PU
PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009294. PubMed ID: 33780481
[TBL] [Abstract][Full Text] [Related]
4. Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis.
Macfarlane CL; Budhathoki SS; Johnson S; Richardson M; Garner P
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD003753. PubMed ID: 30620051
[TBL] [Abstract][Full Text] [Related]
5. Individual Efficacy and Community Impact of Ivermectin, Diethylcarbamazine, and Albendazole Mass Drug Administration for Lymphatic Filariasis Control in Fiji: A Cluster Randomized Trial.
Hardy M; Samuela J; Kama M; Tuicakau M; Romani L; Whitfeld MJ; King CL; Weil GJ; Grobler AC; Robinson LJ; Kaldor JM; Steer AC
Clin Infect Dis; 2021 Sep; 73(6):994-1002. PubMed ID: 33728462
[TBL] [Abstract][Full Text] [Related]
6. A Trial of a Triple-Drug Treatment for Lymphatic Filariasis.
King CL; Suamani J; Sanuku N; Cheng YC; Satofan S; Mancuso B; Goss CW; Robinson LJ; Siba PM; Weil GJ; Kazura JW
N Engl J Med; 2018 Nov; 379(19):1801-1810. PubMed ID: 30403937
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study.
Irvine MA; Stolk WA; Smith ME; Subramanian S; Singh BK; Weil GJ; Michael E; Hollingsworth TD
Lancet Infect Dis; 2017 Apr; 17(4):451-458. PubMed ID: 28012943
[TBL] [Abstract][Full Text] [Related]
8. Mass treatment to eliminate filariasis in Papua New Guinea.
Bockarie MJ; Tisch DJ; Kastens W; Alexander ND; Dimber Z; Bockarie F; Ibam E; Alpers MP; Kazura JW
N Engl J Med; 2002 Dec; 347(23):1841-8. PubMed ID: 12466508
[TBL] [Abstract][Full Text] [Related]
9. Albendazole for lymphatic filariasis.
Critchley J; Addiss D; Gamble C; Garner P; Gelband H; Ejere H;
Cochrane Database Syst Rev; 2005 Oct; (4):CD003753. PubMed ID: 16235339
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Côte d'Ivoire.
Edi C; Bjerum CM; Ouattara AF; Chhonker YS; Penali LK; Méité A; Koudou BG; Weil GJ; King CL; Murry DJ
PLoS Negl Trop Dis; 2019 May; 13(5):e0007325. PubMed ID: 31107869
[TBL] [Abstract][Full Text] [Related]
11. Randomised community-based trial of annual single-dose diethylcarbamazine with or without ivermectin against Wuchereria bancrofti infection in human beings and mosquitoes.
Bockarie MJ; Alexander ND; Hyun P; Dimber Z; Bockarie F; Ibam E; Alpers MP; Kazura JW
Lancet; 1998 Jan; 351(9097):162-8. PubMed ID: 9449870
[TBL] [Abstract][Full Text] [Related]
12. The impact of repeated rounds of mass drug administration with diethylcarbamazine plus albendazole on bancroftian filariasis in Papua New Guinea.
Weil GJ; Kastens W; Susapu M; Laney SJ; Williams SA; King CL; Kazura JW; Bockarie MJ
PLoS Negl Trop Dis; 2008; 2(12):e344. PubMed ID: 19065257
[TBL] [Abstract][Full Text] [Related]
13. An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India.
Jambulingam P; Kuttiatt VS; Krishnamoorthy K; Subramanian S; Srividya A; Raju HKK; Rahi M; Somani RK; Suryaprakash MK; Dwivedi GP; Weil GJ
PLoS Negl Trop Dis; 2021 Feb; 15(2):e0009069. PubMed ID: 33591979
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of ivermectin and albendazole combination in suppressing transmission of lymphatic filariasis following mass administration in Tanzania: a prospective cohort study.
Fimbo AM; Mnkugwe RH; Mlugu EM; Kunambi PP; Malishee A; Minzi OMS; Kamuhabwa AAR; Aklillu E
Infect Dis Poverty; 2024 Jun; 13(1):44. PubMed ID: 38867265
[TBL] [Abstract][Full Text] [Related]
15. Community-based trial of annual versus biannual single-dose ivermectin plus albendazole against Wuchereria bancrofti infection in human and mosquito populations: study protocol for a cluster randomised controlled trial.
de Souza DK; Ahorlu CS; Adu-Amankwah S; Otchere J; Mensah SK; Larbi IA; Mensah GE; Biritwum NK; Boakye DA
Trials; 2017 Oct; 18(1):448. PubMed ID: 28969715
[TBL] [Abstract][Full Text] [Related]
16. An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
Horton J; Witt C; Ottesen EA; Lazdins JK; Addiss DG; Awadzi K; Beach MJ; Belizario VY; Dunyo SK; Espinel M; Gyapong JO; Hossain M; Ismail MM; Jayakody RL; Lammie PJ; Makunde W; Richard-Lenoble D; Selve B; Shenoy RK; Simonsen PE; Wamae CN; Weerasooriya MV
Parasitology; 2000; 121 Suppl():S147-60. PubMed ID: 11386686
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of co-administered diethylcarbamazine, albendazole and ivermectin during mass drug administration for lymphatic filariasis in Haiti: Results from a two-armed, open-label, cluster-randomized, community study.
Dubray CL; Sircar AD; Beau de Rochars VM; Bogus J; Direny AN; Ernest JR; Fayette CR; Goss CW; Hast M; O'Brian K; Pavilus GE; Sabin DF; Wiegand RE; Weil GJ; Lemoine JF
PLoS Negl Trop Dis; 2020 Jun; 14(6):e0008298. PubMed ID: 32511226
[TBL] [Abstract][Full Text] [Related]
18. Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns.
Cano J; Basáñez MG; O'Hanlon SJ; Tekle AH; Wanji S; Zouré HG; Rebollo MP; Pullan RL
Parasit Vectors; 2018 Jan; 11(1):70. PubMed ID: 29382363
[TBL] [Abstract][Full Text] [Related]
19. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis.
Krentel A; Basker N; Beau de Rochars M; Bogus J; Dilliott D; Direny AN; Dubray C; Fischer PU; Ga AL; Goss CW; Hardy M; Howard C; Jambulingam P; King CL; Laman M; Lemoine JF; Mallya S; Robinson LJ; Samuela J; Schechtman KB; Steer AC; Supali T; Tavul L; Weil GJ
PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009002. PubMed ID: 33657090
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Thomsen EK; Sanuku N; Baea M; Satofan S; Maki E; Lombore B; Schmidt MS; Siba PM; Weil GJ; Kazura JW; Fleckenstein LL; King CL
Clin Infect Dis; 2016 Feb; 62(3):334-341. PubMed ID: 26486704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
